San Pedro, CA–August 25, 2007 A potential tumor growth inhibitor and anti-angiogenesis agent for pleural mesothelioma, Phase II testing of sunitinib
Mesothelioma and lung cancer risk after cessation of asbestos exposure. A cohort study of Italian asbestos cement workers
Metabolic imaging has the potential to improve the care of patients receiving chemotherapy for mesothelioma
This entry was posted on Monday, September 24th, 2007 at 10:26 pm and is filed under Asbestos, Medical, Mesothelioma. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
You must be logged in to post a comment.
